In SCLC models, the CHK1 inhibitor, SRA737, in combination with anti-PD-L1 therapy showed good antitumor activity, which also induced the expression of IFN-β and chemokines (CCL5 and CXCL10), increased the infiltration of CD8+ T cells and dendritic cells, and excluded the immunosuppressive cells [170]. This evidence concerns the gene CD274 and small cell lung carcinoma.